Financial Disclosure Reports May Be Required For Pharmacodynamic Studies
Pharmacodynamic studies may be included in "covered" studies for the purposes of FDA's financial disclosure guidance if the study is critical to an application filing.
You may also be interested in...
Pharmaceutical companies that contribute drugs to publicly funded studies used to support marketing applications will be responsible for collecting investigator financial interest information, an updated financial disclosure guidance notes.
Clinical trial sponsors face "prohibitive" costs in developing internal mechanisms to verify clinical investigators' financial interests in the sponsor company, R.W. Johnson's Janice Little said at the Drug Information Association's annual meeting in Baltimore June 29.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011